{"id":"NCT02722278","sponsor":"Clarus Therapeutics, Inc.","briefTitle":"A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men","officialTitle":"A Phase 3, Randomized, Active-controlled, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU) in Hypogonadal Men","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03","primaryCompletion":"2016-11","completion":"2016-11","firstPosted":"2016-03-29","resultsPosted":"2018-02-23","lastUpdate":"2018-02-23"},"enrollment":222,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"BASIC_SCIENCE"},"conditions":["Hypogonadism"],"interventions":[{"type":"DRUG","name":"Oral Testosterone Undecanoate","otherNames":["Oral TU"]},{"type":"DRUG","name":"Axiron Testosterone Topical Solution","otherNames":["Axiron solution"]}],"arms":[{"label":"Oral Testosterone Undecanoate","type":"EXPERIMENTAL"},{"label":"Axiron Testosterone Topical Solution","type":"ACTIVE_COMPARATOR"}],"summary":"A Phase 3, Randomized, Active-controlled, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU) in Hypogonadal Men","primaryOutcome":{"measure":"Number of Oral TU Treated Subjects Who Have a Total T Cavg in the Eugonadal Range of 252 to 907 ng/dL at Visit 7","timeFrame":"Day 105","effectByArm":[{"arm":"Oral Testosterone Undecanoate","deltaMin":145,"sd":null},{"arm":"Axiron Testosterone Topical Solution","deltaMin":48,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":166},"commonTop":["Headache","Haematocrit Increased","Upper respiratory tract infection","High Density Lipoprotein Decreased","Hypertension"]}}